Reference range of rivaroxaban‐calibrated anti‐Xa activity in Chinese children with giant coronary artery aneurysms after KawasakI disease: insights from a population pharmacokinetic and pharmacodynamic analysis
The developed population PK/PD model could be used to describe C<sub>riva</sub> and anti-Xa activity simultaneously. The recommended anti-Xa range could inform rivaroxaban use in Chinese children with GCAA after KD under dual antithrombotic therapy.
Authors
- Bijue Liu (ORCID: https://orcid.org/0009-0003-1171-8587)
- Xiao Zhu (ORCID: https://orcid.org/0000-0003-3295-619X)
- Wen Yao Mak (ORCID: https://orcid.org/0000-0002-8346-2934)
- Leonardo Rodrigues Brandão (ORCID: https://orcid.org/0000-0001-7711-4530)
- Xin Liu (ORCID: https://orcid.org/0009-0009-5595-3195)
- L. Zhang (ORCID: https://orcid.org/0009-0009-4677-5198)
- Fang Liu (ORCID: https://orcid.org/0000-0002-4528-6087)
- Guoying Huang
- Guangan Dai
- Nuo Xu (ORCID: https://orcid.org/0009-0006-6428-8068)
Institutions
- Fudan University (CN)
- Hospital for Sick Children (CA)
- Children's Hospital of Fudan University (CN)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1002/bcp.70324
- Primary Topic
- Kawasaki Disease and Coronary Complications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China